{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:41:29Z","timestamp":1791250889818,"version":"4.1.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Coronary artery disease (CAD)\u2014cardiovascular condition occuring due to atherosclerotic plaque accumulation in the epicardial arteries\u2014is responsible for disabilities of millions of people worldwide and remains the most common single cause of death. Inflammation is the primary pathological mechanism underlying CAD, since is involved in atherosclerotic plaque formation. Glucagon-like peptide-1 (GLP-1) is a peptide hormone which role extends beyond well-known carbohydrates metabolism. In <jats:italic>in vitro<\/jats:italic> studies GLP-1 receptor agonism is associated with regulation of several inflammatory pathways, including cytokine production, lypotoxicity and macrophages differentiation. In this review, we aimed to provide a comprehensive summary of the potential relationship between anti-inflammatory effects of GLP-1 and CAD. We have described a well-established association of anti-inflammatory properties of GLP-1 and atherosclerosis in animals. Pre-clinical studies showed that anti-atherogenic effect of GLP-1 is independent of modulation of plasma lipid levels and depends on anti-inflammatory response. Human studies in this area are limited by small sample size and often nonrandomized character. However, beneficial impact of GLP-1 on endothelial function and microcirculatory integrity in patients with CAD have been described. Understanding atherosclerosis as a chronic inflammatory disease offers new opportunities for the prevention and treatment of CAD. Therefore, we emphasize the need for larger randomized controlled trials focusing on cardiovascular morbidity and mortality to verify the cardioprotective properties of GLP-1R agonists in patients with CAD.<\/jats:p>","DOI":"10.3389\/fcvm.2024.1446468","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T06:19:28Z","timestamp":1734329968000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review"],"prefix":"10.3389","volume":"11","author":[{"given":"Alicja","family":"Skrobucha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patryk","family":"Pindlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Krajewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szymon","family":"Jonik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/mca.0000000000001198","article-title":"Inflammation in coronary artery disease\u2014clinical implications of novel HDL-cholesterol-related inflammatory parameters as predictors","volume":"34","author":"Guo","year":"2023","journal-title":"Coron Artery Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"154819","DOI":"10.1016\/j.cyto.2019.154819","article-title":"Inflammation in atherosclerosis: a key role for cytokines","volume":"122","author":"von Vietinghoff","year":"2019","journal-title":"Cytokine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/biomedicines9070781","article-title":"Inflammatory mechanisms contributing to endothelial dysfunction","volume":"9","author":"Theofilis","year":"2021","journal-title":"Biomedicines"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5491038","DOI":"10.1155\/2022\/5491038","article-title":"Analysis of immune and inflammation characteristics of atherosclerosis from different sample sources","volume":"2022","author":"Nie","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"117152","DOI":"10.1016\/j.lfs.2019.117152","article-title":"Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes","volume":"241","author":"Yaribeygi","year":"2020","journal-title":"Life Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.4065\/mcp.2009.0391","article-title":"Chronic coronary artery disease: diagnosis and management mayo","volume":"84","author":"Cassar","year":"2009","journal-title":"Clin Proc"},{"key":"B9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics\u20142020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","article-title":"GLP-1: molecular mechanisms and outcomes of a complex signaling system","volume":"128","author":"Smith","year":"2019","journal-title":"Neurochem Int"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.jmb.2019.08.009","article-title":"New insights into Beta-cell GLP-1 receptor and cAMP signaling","volume":"432","author":"Tomas","year":"2020","journal-title":"J Mol Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2337\/dc19-1465","article-title":"Vasodilatory actions of glucagon-like peptide 1 are preserved in skeletal and cardiac muscle microvasculature but not in conduit artery in obese humans with vascular insulin resistance","volume":"43","author":"Wang","year":"2020","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1210\/jcem.86.3.7330","article-title":"Action of glucagon and glucagon-like peptide-1-(7\u201336) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo","volume":"86","author":"Bertin","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"888","DOI":"10.2337\/db11-1073","article-title":"Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism","volume":"61","author":"Chai","year":"2012","journal-title":"Diabetes"},{"key":"B16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1042\/CS20130708","article-title":"GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans","volume":"127","author":"Subaran","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1152\/ajprenal.00394.2015","article-title":"The physiological role of glucagon-like peptide-1 in the regulation of renal function","volume":"310","author":"Farah","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e230284","DOI":"10.1530\/ec-23-0284","article-title":"Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy","volume":"12","author":"Shi","year":"2023","journal-title":"Endocr Connect"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/WNR.0b013e32832fbf14","article-title":"Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system","volume":"20","author":"Hamilton","year":"2009","journal-title":"Neuroreport"},{"key":"B20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/00207454.2021.1924707","article-title":"The pleiotropic of GLP-1\/GLP-1R axis in central nervous system diseases","volume":"133","author":"Zhang","year":"2023","journal-title":"Int J Neurosci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijcard.2019.04.039","article-title":"Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: a target to modulate cardiovascular risk?","volume":"292","author":"Dozio","year":"2019","journal-title":"Int J Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/eurjpc\/zwad050","article-title":"Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies","volume":"30","author":"Malavazos","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3094642","DOI":"10.1155\/2016\/3094642","article-title":"Anti-Inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2015","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"key":"B25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2023.03.016","article-title":"Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice","volume":"372","author":"van Eenige","year":"2023","journal-title":"Atherosclerosis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.atherosclerosis.2013.08.033","article-title":"Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9\u201337) and GLP-1(28\u201337) stabilize atherosclerotic lesions in apoe(-)\/(-) mice","volume":"231","author":"Burgmaier","year":"2013","journal-title":"Atherosclerosis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.atherosclerosis.2022.03.032","article-title":"Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis","volume":"352","author":"Jensen","year":"2022","journal-title":"Atherosclerosis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/bph.12490","article-title":"Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration","volume":"171","author":"Wang","year":"2014","journal-title":"Br J Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice","volume":"54","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.peptides.2013.12.015","article-title":"A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis","volume":"54","author":"Tashiro","year":"2014","journal-title":"Peptides"},{"key":"B32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1124\/jpet.119.258343","article-title":"Liraglutide attenuates preestablished atherosclerosis in apolipoprotein E-deficient mice via regulation of immune cell phenotypes and proinflammatory mediators","volume":"370","author":"Bruen","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1172\/JCI75005","article-title":"Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression","volume":"127","author":"Rahman","year":"2017","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12933-017-0626-3","article-title":"Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","volume":"16","author":"Bruen","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","article-title":"Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury","volume":"54","author":"Bose","year":"2005","journal-title":"Diabetes"},{"key":"B36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","article-title":"Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury","volume":"53","author":"Timmers","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1111\/dom.13472","article-title":"Myocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacity","volume":"20","author":"Diebold","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","article-title":"The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype","volume":"60","author":"Vinu\u00e9","year":"2017","journal-title":"Diabetologia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","article-title":"Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion","volume":"109","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2337\/dc10-1949","article-title":"The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an \u201cendothelial resistance\u201d to glucagon-like peptide 1 in diabetes","volume":"34","author":"Ceriello","year":"2011","journal-title":"Diabetes Care"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5568159","DOI":"10.1155\/2021\/5568159","article-title":"Effect of GLP-1\/GLP-1R on the polarization of macrophages in the occurrence and development of atherosclerosis","volume":"2021","author":"Yang","year":"2021","journal-title":"Mediators Inflamm"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1161\/ATVBAHA.113.301586","article-title":"Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study","volume":"33","author":"Woo","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2. Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1111\/dom.13761","article-title":"Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial","volume":"21","author":"Anholm","year":"2019","journal-title":"Diabetes Obes Metab"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1446468\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T06:19:30Z","timestamp":1734329970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1446468\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":49,"alternative-id":["10.3389\/fcvm.2024.1446468"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1446468","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"article-number":"1446468"}}